IN THE UNITED STATES PATENT AND TRADMARK OFFICE

blicants: Breitenbach, et al.

ial No.: 10/650,178

Filed: August 28, 2003

Title: SOLID PHARMACEUTICAL

DOSAGE FORM

Case No.: 7113US01

Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 on:

Date of Deposit: February 9, 2004

Tanya Parent

Date

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled SOLID PHARMACEUTICAL DOSAGE FORM are the following:

- 1. Information Disclosure Statement;
- 2. Form PTO 1449, in duplicate;
- 3. Reference as cited on PTO 1449 (17 reference); and
- 4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7835 Facsimile: (847) 938-2623 Respectfully submitted, Breitenbach ét al.

///////

Kalim S. Fuzail /

Registration No. 45,805 Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

plicants: Breitenbach, et al.

Serial No.: 10/650,178

Filed: August 28, 2003

Title: SOLID PHARMACEUTICAL

DOSAGE FORM

Case No.: 7113US01

Group Art No.: 1615

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: February 9, 2004

Julya_

Date

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7835 Facsimile: (847) 938-2623 Breitenbach, et al.

Respectfully submitted,

Kalim S. Fuzail

Registration No. 45,805 Attorney for Applicants



DATE: February 9, 2004 SHEET _1_ of _1_

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO. 7113US01			SERIAL NO. 10/650,178		
		FORMATION DISCLOS ATEMENT BY APPLIC		APPLICANT(S) Breitenbach, et al.						
(37 CFR 1.98 (Jse several sheets if neces	sary)	FILING DATE August 28, 2003			GROUP 1615			
<u>(</u> <u>-</u>	<u>-//</u>		U.S.PATENT	r DOC	CUMENTS			1		
EXAMINER INITIAL	1	PATENT NUMBER	ISSUE DATE		VENTOR	CLASS		UB	FILIN	
INITIAL	A1	5,541,206	07/30/1996		of et al.	CLASS	CL	ASS	DAT	E
····	A2	5,648,497	07/15/1997	Kemp	of et al.					
	A3	5,914,332	06/22/1999	Sham	et al.			-		
	FOR	EIGN PATENT O	P PURLISHE	D FO	REIGN PA	TENT A	PPI	ICATI		
	T OK	DOCUMENT	PUBLIC-ATION	С	OUNTRY OF	CLA		SUB	TRA	NS-
		NUMBER	DATE	PA	TENT OFFIC	E		CLASS	LAT YES	ION
	ВТ	00/57854	04.10.2000	- wo)				X	
	B2	00/74677	14.12.2000	wo)					
	В3	01/00175	04.01.2001	WC)			.,		
	B4	01/22938	05.04.2001	 wo)					
	B5	01/34118	17.05.2001	WC)					
	В6	01/52821	26.07.2001	 wc)					
	В7	01/91727	06.12.2001	 wc)				X	
	B8	02/092595	21.11.2002	wo)			-		
	В9	95/07696	23.03.1995	WC)					
	B10	98/22106	28.05.1998	wo)					-
	ВП	0942721	22.01.2003	EP			-			
	B12	0732923	12.12.2001	EP						
		OTHER DOCUM	ENTS (Includin	g Auth	or, Title, Date	e, Place of	Public	cation)		
	CI	Aungst et al., "Am soluble HIV protea Pharmaceutics 156	phiphilic vehicuse inhibitor at :79-88 (1997)	les im high d	prove the or oses," Inter	ral bioava national J	ilabi Iourn	lity of a al of	•	•
	C2	Chiou et al., "Phar Sci. 60(9):1281-13	maceutical app	licatio	ns of solid o	dispersion	ı sysi	tems," J	. Phai	m.
EXAMINER		L		DA	TE CONSID	ERED				
EXAMINER	Initial	itation considered. Dray	v line through cito							
not considered	d. Inclu	de copy of this form with	next communicat	ion to a	oplicant.	anu				